XOMA Royalty Reports Strong 2024 Financial Growth

Xoma Corp. ( (XOMA) ) has released its Q4 earnings. Here is a breakdown of the information Xoma Corp. presented to its investors.

XOMA Royalty Corporation is a biotechnology royalty aggregator focused on acquiring potential future economics from therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company reported its financial results for the fourth quarter and full year of 2024, highlighting significant growth in its royalty and milestone portfolio, which doubled to over 120 assets through five transactions. XOMA also completed two company acquisitions and received FDA approval for two drugs in 2024.

In 2024, XOMA Royalty achieved cash receipts of $46.3 million, with $4.0 million in the fourth quarter alone. The company expanded its commercial royalty portfolio with six assets, including VABYSMO, OJEMDA, and MIPLYFFA, and added 11 assets to its Phase 3 portfolio, promising key readouts in 2025. XOMA’s strategic acquisitions and partnerships, such as those with Twist Bioscience and Daré Bioscience, have strengthened its position in the biotech sector.

Financially, XOMA reported total income and revenues of $28.5 million for 2024, a significant increase from $4.8 million in 2023. Despite a net loss of $13.8 million for the year, primarily due to non-cash credit losses, the company is optimistic about becoming cash flow positive in the near future. The acquisitions of Kinnate Biopharma and Pulmokine Inc. added valuable assets to XOMA’s portfolio, further enhancing its growth prospects.

Looking ahead, XOMA Royalty is well-positioned with over $100 million in cash and a clear path to sustainable cash flow from royalties. The company anticipates several key developments in 2025, including Phase 3 study results and potential new product approvals, which could drive further value for both patients and shareholders.